When does the tafamidis patent expire?
I can’t determine a specific “tafamidis patent expiry date” from the information provided here. Patent expiry depends on the exact patent(s) and jurisdiction (country/state) and can vary by patent family, filing/grant dates, and any extensions (for example, supplementary protection certificates in some countries).
Which patents control tafamidis exclusivity?
Exclusivity timing is usually driven by one or more of the following, depending on the country:
- The first (earliest) filing date in the relevant patent family
- Product-specific secondary patents (formulations, dosages, or uses)
- Patent-term adjustments/guarantees (where applicable)
- Extensions such as supplementary protection certificates (SPCs) in jurisdictions that use them
What country matters most for tafamidis expiry?
You’ll get different expiry dates depending on where you mean:
- US (often follows patent grant/term rules plus possible adjustments)
- EU/UK (often involves SPCs alongside patent term)
- Other countries (Japan, Canada, etc., each have their own rules)
What I need from you to give an exact expiry date
Reply with:
1) The country (e.g., US, EU, UK, Japan), and
2) Whether you mean the first generic-legal “patent expiry” or the broader “market exclusivity” window (if known), and
3) If you’re targeting a specific product brand (tafamidis capsules vs tafamidis meglumine), if relevant.
If you just want the earliest likely timing
If you share the earliest priority year or a patent number for tafamidis you’ve been looking at, I can help translate that into an expected expiry window for the jurisdiction you name.
Sources: None provided.